Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Carotid Intima-Media Thickness Versus Carotid Plaque Burden for Predicting Cardiovascular Risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Open Versus Endovascular Stent Graft Repair of Abdominal Aortic Aneurysms: Do We Need More Randomized Clinical Trials?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effect of spirapril and hydrochlorothiazide on platelet function and euglobulin clot lysis time in patients with mild hypertension

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Characterization of Blood Pressure and Heart Rate Oscillations in POTS Patients via Uniform Phase Empirical Mode Decomposition

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Investigating the aetiology of adverse events following HPV vaccination with systems vaccinology

    Research output: Contribution to journalReviewResearchpeer-review

  3. A model-based analysis of autonomic nervous function in response to the Valsalva maneuver

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. An optimal control approach for blood pressure regulation during head-up tilt

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
The anemia in patients with chronic renal failure can be corrected through treatment with recombinant human erythropoietin treatment. This correction is associated with changes in the rheologic variables, which could explain the changes in hemodynamics found by many investigators. The authors have followed up 11 patients with chronic renal failure on hemodialysis before and during six months of therapy with erythropoietin. The measurements were made before treatment, after four months of therapy, and after six months of therapy. The measurements included hematocrit, osmotic resistance of the red blood cells, red blood cell volume, plasma volume, heart rate, arterial blood pressure, and cardiac output measured by the indicator dilution method. They found a significant increase in hematocrit hemoglobin, and red blood cell volume and a decrease in osmotic resistance while the hemodynamic variables were unchanged. The conclude that, in spite of changes in rheologic variables, increasing viscosity of the blood and thus possibly increasing the peripheral resistance, these had no effect on the cardiovascular state. Erythropoietin treatment improves the subjective well-being in patients on chronic hemodialysis without compromising their cardiovascular function.
Original languageEnglish
JournalAngiology
Volume45
Issue number3
Pages (from-to)231-4
Number of pages4
ISSN0003-3197
Publication statusPublished - 1 Mar 1994

ID: 32354124